The current financial score of Jaguar Health Inc is 5.42. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.23M, representing a year-over-year decrease of 58.88%, while its net profit experienced a year-over-year decrease of 22.04%.
The current valuation score of Jaguar Health Inc is 8.60. Its current P/E ratio is -0.00, which is -23721.05% below the recent high of 0.90 and -7873.68% above the recent low of -0.30.
No earnings forecast score is currently available for Jaguar Health Inc. The Pharmaceuticals industry's average is 7.83. The average price target is 16.00, with a high of 16.00 and a low of 16.00.
The current price momentum score of Jaguar Health Inc is 8.02. Currently, the stock price is trading between the resistance level at 11.40 and the support level at -1.85, making it suitable for range-bound swing trading.
The current institutional shareholding score of Jaguar Health Inc is 3.00. The latest institutional shareholding proportion is 0.83%, representing a quarter-over-quarter decrease of 69.80%.
The current risk assessment score of Jaguar Health Inc is 1.37. The company's beta value is -0.07. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.